HCV NS5A inhibitor — Zepatier component (50 mg elbasvir + 100 mg grazoprevir, once daily for genotype 1 or 4 HCV). Modest CYP3A4 substrate; not a strong inhibitor at clinical doses. The combo is taken with or without ribavirin depending on cirrhosis status and prior treatment failure. PK (Zepatier label, 50 mg PO qd SS): Cmax 121 ng/mL, AUC 1920 ng·h/mL, Tmax 3 h (range 3-6), t½ 24 h, F 32%. High-fat meal effect on elbasvir is modest (~15%). Steady state by ~6 days. CYP3A4 substrate; strong inhibitors require dose adjustment.
Half-Life & Elimination Curve (PO: 24h)
Plasma (PO)t½ Decay (24h)
0×t½0h100%(46.6 µg/L)
1×t½24h50%(23.3 µg/L)
2×t½48h25%(11.7 µg/L)
3×t½3d12.5%(5.83 µg/L)
4×t½4d6.3%(2.92 µg/L)
5×t½5d3.1%(1.46 µg/L)
Elimination t½24h (PO)
Rate Constant (ke)0.0289 h⁻¹
Time to Peak (Tmax)6.05h
Est. Peak (Cmax)46.6 µg/L
Clearance (CL)8.32 L/h
97% Washout (5×t½)5d
Dosing Guidelines
Oral (PO): Typical 50 mg
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 32% · Volume of Distribution (Vd): 288 L · Absorption (ka): 0.5 h⁻¹ (t½ka ≈ 1.39h)